Ubs Asset Management Americas Inc Bicycle Therapeutics PLC Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 5,100 shares of BCYC stock, worth $41,922. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,100Holding current value
$41,922% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BCYC
# of Institutions
101Shares Held
42.8MCall Options Held
15.6KPut Options Held
27.7K-
Baker Bros. Advisors LP New York, NY10.9MShares$89.5 Million1.1% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$30.3 Million0.08% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$28.4 Million7.08% of portfolio
-
Armistice Capital, LLC New York, NY2.67MShares$22 Million0.35% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$21.8 Million0.12% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $244M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...